| P50 | author | Carl Turesson | Q88917424 |
| | Lennart T. H. Jacobsson | Q110625350 |
| P2093 | author name string | Eric L Matteson | |
| P2860 | cites work | Reporting of mortality in a psoriatic arthritis clinic is primarily a function of the number of clinic contacts and not disease severity | Q81581683 |
| | Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis | Q81922641 |
| | CD56-expressing T cells that have features of senescence are expanded in rheumatoid arthritis | Q79461195 |
| | Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study | Q79850163 |
| | Long-term prognosis and causes of death in systemic lupus erythematosus | Q80056471 |
| | Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis | Q80111107 |
| | Inflammatory rheumatic disease and smoking are predictors of aortic inflammation: a controlled study of biopsy specimens obtained at coronary artery surgery | Q80388334 |
| | Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation | Q80932706 |
| | Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis | Q80969856 |
| | Use of low-dose glucocorticoids and the risk of cardiovascular morbidity and mortality in rheumatoid arthritis: what is the true direction of effect? | Q81312678 |
| | Cardiovascular death in rheumatoid arthritis: a population-based study | Q81484761 |
| | Prediction of Coronary Heart Disease Using Risk Factor Categories | Q22241923 |
| | Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials | Q24546221 |
| | Atherosclerosis — An Inflammatory Disease | Q26776972 |
| | Cardiovascular risk factors in women with and without rheumatoid arthritis | Q28171426 |
| | Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study | Q28281870 |
| | Can intervention modify adverse lifestyle variables in a rheumatoid population? Results of a pilot study | Q28344607 |
| | Inflammation, atherosclerosis, and coronary artery disease | Q29547232 |
| | Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis | Q33563669 |
| | Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis | Q33565333 |
| | Three year follow-up of body composition changes in pre-menopausal women with systemic lupus erythematosus | Q33639239 |
| | Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus | Q33974679 |
| | Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus | Q34098573 |
| | Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis | Q34182804 |
| | Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis | Q34283776 |
| | Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial | Q34327988 |
| | Prescribing exercise as preventive therapy | Q34461574 |
| | Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk | Q34518911 |
| | Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project | Q34534248 |
| | Obesity as compared with physical activity in predicting risk of coronary heart disease in women | Q34564627 |
| | Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison | Q34582722 |
| | Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations | Q34712199 |
| | Unraveling pleiotropic effects of statins on plaque rupture | Q34993911 |
| | Anti-TNFalpha therapy for rheumatoid arthritis: an update. | Q35065119 |
| | Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management | Q35179614 |
| | Osteoarthritis of finger joints in Finns aged 30 or over: prevalence, determinants, and association with mortality | Q35552336 |
| | Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. | Q35553700 |
| | Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study | Q35554431 |
| | Change in and predictors of leisure activities among patients with rheumatoid arthritis: a prospective study. | Q50767330 |
| | Osteoarthritis as a determinant of an adverse coronary heart disease risk profile. | Q50962550 |
| | Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. | Q50969877 |
| | Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. | Q51032043 |
| | Endothelial dysfunction of peripheral arteries in patients with immunohistologically confirmed myocardial inflammation correlates with endothelial expression of human leukocyte antigens and adhesion molecules in myocardial biopsies. | Q52035977 |
| | Co-stimulatory pathways controlling activation and peripheral tolerance of human CD4+CD28- T cells | Q56908440 |
| | High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors | Q57307115 |
| | Baseline levels of c-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis : A ten-year followup study of a primary care-based inception cohort | Q57804967 |
| | Modulation of CD4 + CD28 null T Lymphocytes by Tumor Necrosis Factor-α Blockade in Patients With Unstable Angina | Q58230246 |
| | Perturbation of the T-Cell Repertoire in Patients With Unstable Angina | Q58230319 |
| | Mortality studies in psoriatic arthritis. Results from a single outpatient clinic. I. Causes and risk of death | Q60700017 |
| | Modulation of CD28 expression with anti-tumor necrosis factor α therapy in rheumatoid arthritis | Q61711491 |
| | Physical activity levels among the general US adult population and in adults with and without arthritis | Q64127330 |
| | The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales | Q70606503 |
| | Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study | Q73106702 |
| | Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset | Q73292550 |
| | Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects | Q73628316 |
| | Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus | Q77909409 |
| | Lipid profiles in untreated patients with rheumatoid arthritis | Q78139431 |
| | How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH | Q78482942 |
| | Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years | Q78794833 |
| | Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis | Q35638369 |
| | Endothelial expression of MHC class II molecules in autoimmune disease | Q35644284 |
| | Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy | Q35676074 |
| | Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? | Q35805168 |
| | Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk | Q35876331 |
| | Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis | Q35953268 |
| | All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists | Q35954490 |
| | What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. | Q35954625 |
| | Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis | Q35988930 |
| | Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions | Q36101622 |
| | Reducing the cardiovascular disease burden in rheumatoid arthritis | Q36426046 |
| | The repertoire of CD4+ CD28- T cells in rheumatoid arthritis | Q36437991 |
| | Mechanisms of disease: atherosclerosis in autoimmune diseases | Q36577423 |
| | Cardiovascular risk factors, fitness and physical activity in rheumatic diseases | Q36728516 |
| | Cardiovascular events in systemic lupus erythematosus and rheumatoid arthritis : emerging concepts, early diagnosis and management. | Q36795616 |
| | Exercise and arthritis. The hematology of inactivity | Q37793600 |
| | Risk factors for developing systemic lupus erythematosus: a case-control study in southern Sweden | Q38489239 |
| | Projections of US prevalence of arthritis and associated activity limitations | Q40361739 |
| | Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. | Q40461525 |
| | Predicting mortality in patients with rheumatoid arthritis | Q40582797 |
| | Recreational exercise in arthritis | Q41141976 |
| | Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes | Q42628689 |
| | Rheumatoid arthritis and mortality. A longitudinal study in Pima Indians. | Q43616578 |
| | Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis | Q43622165 |
| | Risk factors for cardiovascular disease in systemic lupus erythematosus | Q43767819 |
| | Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians | Q44170460 |
| | Effects of physical activity on life expectancy with cardiovascular disease | Q44535958 |
| | All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. | Q44724213 |
| | Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults | Q44851038 |
| | Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study | Q44973310 |
| | Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice | Q45042448 |
| | Moderate to high intensity conditioning leisure time physical activity and high cardiorespiratory fitness are associated with reduced plasma fibrinogen in eastern Finnish men. | Q45056552 |
| | C-reactive protein levels and outcomes after statin therapy | Q45213511 |
| | Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation | Q46414172 |
| | CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients | Q47438401 |
| | Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis | Q48502988 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cardiovascular disease | Q389735 |
| | circulatory system | Q11068 |
| | rheumatism | Q684924 |
| P304 | page(s) | 605-614 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Vascular Health and Risk Management | Q7916443 |
| P1476 | title | Cardiovascular co-morbidity in rheumatic diseases | |
| P478 | volume | 4 | |